Agilent, GKSA-312, AdvanceBio 2-AA G2S2 α(2,6) / A2G2S(6)2 N-glycan standard (formerly ProZyme)

AdvanceBio 2-AA G2S2 α(2,6) / A2G2S(6)2 N-glycan standard (formerly ProZyme). N-glycan (di-sialylated, galactosylated biantennary) labeled with 2-aminobenzoic acid (2-AA, also known as anthranilic acid), for use as a qualitative standard in applications such as liquid chromatography (LC). Alternative glycan names: G2S2, A2G2S2, A2G(4)2S(6)2, A2.

Specifications:
Chemical Structure:
Label: 2-AA
Monoisotopic Mass: MWGlycan + 121.05276 = 2343.8357
Name: G2S2 (α2,6)
Oxford Name: A2G(4)2S(6)2
Standard Type: Complex-type Native N-Glycan
Unit: 100 pmol

**********The following product description is generated by AI and is for reference only. If you have any questions, please contact customer service.**********
The AdvanceBio 2-AA G2S2 α(2,6) / A2G2S(6)2 N-glycan standard is a high-purity, 2-aminobenzoic acid labeled N-glycan reference, designed to facilitate accurate structure assignment and quantitation in glycan analysis. This standard supports robust method validation and system suitability testing, ensuring reproducible performance across workflows involving N-glycan profiling. Ideal for biopharmaceutical development, quality control, and academic research, it aids in characterizing complex glycoproteins such as monoclonal antibodies and therapeutic proteins.

Compatible with leading analytical platforms—such as HPLC, UHPLC, and LC-MS systems—this standard integrates seamlessly with Agilent's AdvanceBio Glycan Mapping workflow and associated columns. Its reliable, well-defined structure is tailored for method optimization and serves as a critical positive control in both qualitative and quantitative studies. When used alongside other AdvanceBio N-glycan standards and consumables, researchers can streamline glycomic analyses and ensure high-confidence data. This product is an essential tool for laboratories focused on glycosylation profiling, batch comparability, and regulatory compliance. Backed by Agilent's quality assurance, it delivers consistent, reproducible results to advance glycan research and biotherapeutic development.